Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer

Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer

Colorectal cancer is one of the most frequent malignancies in humans and an important cause of cancer death. Metastatic colorectal cancer remains incurable with available systemic therapeutic options. The most active cytotoxic drug against this malignancy, the antimetabolite 5-fluorouracil, was deve...

Full description

Bibliographic Details
Main Authors:	I. Grivicich, D.R.A. Mans, G.J. Peters, G. Schwartsmann
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica 2001-09-01
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	colorectal carcinoma 5-fluorouracil irinotecan oxaliplatin
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000900001

Similar Items

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
by: Takuya Tsujino, et al.
Published: (2017-04-01)

Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells
by: Bernd Frerker, et al.
Published: (2023-06-01)

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
by: Hélène Bellio, et al.
Published: (2021-10-01)

Results of using tegafur in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer
by: N. V. Dobrova, et al.
Published: (2018-11-01)

FTORAFUR IN COMBINATION WITH OXALIPLATIN AND IRINOTECAN IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER: PRELIMINARY RESULTS
by: N. V. Dobrova, et al.
Published: (2018-02-01)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
by: Jinwei Zhu, et al.
Published: (2023-09-01)

Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study
by: Xiu Liu, et al.
Published: (2022-07-01)

Time-Tested Strategies in Modern Context: A Bibliometric Study of Chemotherapy’s Continued Importance in Colorectal Cancer Treatment
by: Helena Clar-Marmaneu, et al.
Published: (2023-09-01)

Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) ± Leucovorin in patients with advanced colorectal cancer
by: N. V. Dobrova, et al.
Published: (2019-12-01)

Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF-κB Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury
by: Bin Huang, et al.
Published: (2022-12-01)

Triple combination of irinotecan + oxaliplatin + 5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer: first experience with a new treatment regimen
by: A. D. Darenskaya, et al.
Published: (2018-05-01)

Oxaliplatin versus Irinotecan no câncer colorretal avançado
by: Thais Arabe Prado, et al.
Published: (2022-11-01)

The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments
by: Angelina Pranteda, et al.
Published: (2020-04-01)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
by: Chu Matsuda, et al.
Published: (2023-01-01)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Höhler Thomas, et al.
Published: (2004-07-01)

Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS<sup>G12C</sup>-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis
by: Vincenzo Formica, et al.
Published: (2023-06-01)

CHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHES
by: N. V. Dobrova, et al.
Published: (2017-11-01)

Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy
by: Manisha Chandar, et al.
Published: (2015-03-01)

The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma
by: Francesca Crudele, et al.
Published: (2021-08-01)

Metformin Enhancement of Therapeutic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells and Nude Mice
by: Kwan-Ling Yip, et al.
Published: (2022-04-01)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
by: Mashiro Okunaka, et al.
Published: (2021-04-01)

IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2008-09-01)

Prognostic value of Bax expression in the primary colon tumor of patients with metastatic colorectal cancer receiving first-line treatment with a triple combination of irinotecan + oxaliplatin + long-term infusion of 5-fluorouracil
by: A. D. Darenskaya, et al.
Published: (2019-06-01)

Ischemic Colitis of the Transverse Colon Induced by 5-Fluorouracil, Leucovorin, and Irinotecan: A Case Report
by: Fezzeh Elyasinia, et al.
Published: (2022-06-01)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
by: Amol Gupta, et al.
Published: (2023-08-01)

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
by: Ai-Wei Feng, et al.
Published: (2022-09-01)

Irinotecan-Induced Dysarthria
by: Albertine J. Dressel, et al.
Published: (2012-01-01)

Evaluation of response, tolerability and toxicity of new chemotherapeutic regimen in advanced Gastric Cancer
by: Mohammad Ali Mashhadi
Published: (2009-01-01)

Evaluation of response, tolerability and toxicity of new chemotherapeutic regimen in advanced Gastric Cancer
by: Mohammad Ali Mashhadi
Published: (2009-03-01)

Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy
by: Gao Z, et al.
Published: (2017-09-01)

A Perspective on the Role of Microbiome for Colorectal Cancer Treatment
by: Sanjna Kalasabail, et al.
Published: (2021-09-01)

Unprecedented Simultaneous and Rapid Reversal of Oral and Alimentary Mucositis using Polymerized Cross Linked Sucralfate: Two Case Reports
by: Ricky Wayne McCullough
Published: (2014-12-01)

<it>Let-7</it> miRNA-binding site polymorphism in the <it>KRAS</it> 3<sup>′</sup>UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab
by: Kjersem Janne B, et al.
Published: (2012-11-01)

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
by: Bei Yue, et al.
Published: (2021-11-01)

Inhibition of insulin‐like growth factor 2 mRNA‐binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics
by: Nicole Betson, et al.
Published: (2022-12-01)

Irinotecan in the treatment of colorectal cancer. A literature review
by: V. A. Ivanov, et al.
Published: (2017-04-01)

5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro
by: Eline Vanlancker, et al.
Published: (2017-11-01)

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
by: Masanobu Tsubaki, et al.
Published: (2023-04-01)

Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines
by: Mahshid Mohammadian, et al.
Published: (2017-01-01)

The Prognostic and Predictive Value of SOX2<sup>+</sup> Cell Densities in Patients Treated for Colorectal Cancer
by: Tim J. Miller, et al.
Published: (2020-04-01)